Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit

Vaccine

Volumn 28, Issue 8, 2010, Pages 1962-1974

  Valentin, Antonio ^a   von Gegerfelt, Agneta ^a   Rosati, Margherita ^a   Miteloudis, Georgios ^a   Alicea, Candido ^a   Bergamaschi, Cristina ^a   Jalah, Rashmi ^a   Patel, Vainav ^a   Khan, Amir S ^b   Draghia Akli, Ruxandra ^b   Pavlakis, George N ^a   Felber, Barbara K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VGX Pharmaceuticals Inc   (United States)

Author keywords

Central memory; DNA vaccines; Effector memory; HIV; Therapeutic vaccination; Viral load

Indexed keywords

DIDANOSINE; DNA VACCINE; EMTRICITABINE; GAMMA INTERFERON; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 2; INTERLEUKIN 5; PLASMID DNA; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; ELECTROPORATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNE RESPONSE; IN VIVO STUDY; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VIREMIA; VIROLOGY; VIRUS GENE; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, VIRAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; ELECTROPORATION; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; INTERLEUKIN-15; MACACA MULATTA; PLASMIDS; RECEPTORS, INTERLEUKIN-15; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VACCINES, DNA; VIRAL LOAD; VIREMIA;

EID: 76949100672     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.099     Document Type: Article

References (89)

1. Lisziewicz J., Trocio J., Xu J., Whitman L., Ryder A., Bakare N., et al. Control of viral rebound through therapeutic immunization with DermaVir. Aids 19 (2005) 35-43
2. Lori F., Trocio J., Bakare N., Kelly L.M., and Lisziewicz J. DermaVir, a novel HIV immunisation technology. Vaccine 23 (2005) 2030-2034
3. Fuller D.H., Rajakumar P.A., Wu M.S., Mcmahon C.W., Shipley T., Fuller J.T., et al. DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued. Virology 348 (2006) 200-215
4. Lisziewicz J., Calarota S.A., and Lori F. The potential of topical DNA vaccines adjuvanted by cytokines. Expert Opin Biol Ther 7 (2007) 1563-1574
5. von Gegerfelt A.S., Rosati M., Alicea C., Valentin A., Roth P., Bear J., et al. Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. J Virol 81 (2007) 1972-1979
6. Halwani R., Boyer J.D., Yassine-Diab B., Haddad E.K., Robinson T.M., Kumar S., et al. Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol 180 (2008) 7969-7979
7. Zur Megede J., Sanders-Beer B., Silvera P., Golightly D., Bowlsbey A., Hebblewaite D., et al. A therapeutic SIV DNA vaccine elicits T-Cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques. AIDS Res Hum Retroviruses 24 (2008) 1103-1116
8. Hel Z., Venzon D., Poudyal M., Tsai W.P., Giuliani L., Woodward R., et al. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med 6 (2000) 1140-1146
9. Tryniszewska E., Nacsa J., Lewis M.G., Silvera P., Montefiori D., Venzon D., et al. Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J Immunol 169 (2002) 5347-5357
10. Lu W., Wu X., Lu Y., Guo W., and Andrieu J.M. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 9 (2003) 27-32
11. De Rose R., Fernandez C.S., Smith M.Z., Batten C.J., Alcantara S., Peut V., et al. Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood. PLoS Pathog 4 (2008) e1000055
12. Lori F., Kelly L.M., and Lisziewicz J. Immunological approaches for HIV therapy. Curr Drug Targets Infect Disord 3 (2003) 171-178
13. Rosenberg E.S., Altfeld M., Poon S.H., Phillips M.N., Wilkes B.M., Eldridge R.L., et al. Immune control of HIV-1 after early treatment of acute infection. Nature 407 (2000) 523-526
14. Markowitz M., Jin X., Hurley A., Simon V., Ramratnam B., Louie M., et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 186 (2002) 634-643
15. Lu W., Arraes L.C., Ferreira W.T., and Andrieu J.M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 10 (2004) 1359-1365
16. Kinloch-De Loes S., Hoen B., Smith D.E., Autran B., Lampe F.C., Phillips A.N., et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 192 (2005) 607-617
17. Levy Y., Gahery-Segard H., Durier C., Lascaux A.S., Goujard C., Meiffredy V., et al. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. Aids 19 (2005) 279-286
18. Tubiana R., Carcelain G., Vray M., Gourlain K., Dalban C., Chermak A., et al. Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). Vaccine 23 (2005) 4292-4301
19. Andrieu J.M., and Lu W. A dendritic cell-based vaccine for treating HIV infection: background and preliminary results. J Intern Med 261 (2007) 123-131
20. Hardy G.A., Imami N., Nelson M.R., Sullivan A.K., Moss R., Aasa-Chapman M.M., et al. A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy. J Immune Based Ther Vaccines 5 (2007) 6
21. Connolly N.C., Whiteside T.L., Wilson C., Kondragunta V., Rinaldo C.R., and Riddler S.A. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol 15 (2008) 284-292
22. Pialoux G., Quercia R.P., Gahery H., Daniel N., Slama L., Girard P.M., et al. Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study. Clin Vaccine Immunol 15 (2008) 562-568
23. Wilson C.C., Newman M.J., Livingston B.D., Mawhinney S., Forster J.E., Scott J., et al. Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy. Clin Vaccine Immunol 15 (2008) 986-994
24. Aihara H., and Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 16 (1998) 867-870
25. Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 6 (1999) 508-514
26. Rizzuto G., Cappelletti M., Maione D., Savino R., Lazzaro D., Costa P., et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci U S A 96 (1999) 6417-6422
27. Selby M., Goldbeck C., Pertile T., Walsh R., and Ulmer J. Enhancement of DNA vaccine potency by electroporation in vivo. J Biotechnol 83 (2000) 147-152
28. Widera G., Austin M., Rabussay D., Goldbeck C., Barnett S.W., Chen M., et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 164 (2000) 4635-4640
29. Mir L.M. Therapeutic perspectives of in vivo cell electropermeabilization. Bioelectrochemistry 53 (2001) 1-10
30. Wang Z., Troilo P.J., Wang X., Griffiths T.G., Pacchione S.J., Barnum A.B., et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther 11 (2004) 711-721
31. Prud'homme G.J., Glinka Y., Khan A.S., and Draghia-Akli R. Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther 6 (2006) 243-273
32. Draghia-Akli R., Khan A.S., Brown P.A., Pope M.A., Wu L., Hirao L., et al. Parameters for DNA vaccination using adaptive constant-current electroporation in mouse and pig models. Vaccine 26 (2008) 5230-5237
33. Otten G., Schaefer M., Doe B., Liu H., Srivastava I., Zur Megede J., et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22 (2004) 2489-2493
34. Otten G.R., Schaefer M., Doe B., Liu H., Megede J.Z., Donnelly J., et al. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine 24 (2006) 4503-4509
35. Luckay A., Sidhu M.K., Kjeken R., Megati S., Chong S.Y., Roopchand V., et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 81 (2007) 5257-5269
36. Hirao L.A., Wu L., Khan A.S., Hokey D.A., Yan J., Dai A., et al. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 26 (2008) 3112-3120
37. Rosati M., Valentin A., Jalah R., Patel V., von Gegerfelt A., Bergamaschi C., et al. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 26 (2008) 5223-5229
38. Rosati M., von Gegerfelt A., Roth P., Alicea C., Valentin A., Robert-Guroff M., et al. DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol 79 (2005) 8480-8492
39. Schwartz S., Campbell M., Nasioulas G., Harrison J., Felber B.K., and Pavlakis G.N. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J Virol 66 (1992) 7176-7182
40. Schwartz S., Felber B.K., and Pavlakis G.N. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol 66 (1992) 150-159
41. Nasioulas G., Zolotukhin A.S., Tabernero C., Solomin L., Cunningham C.P., Pavlakis G.N., et al. Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA. J Virol 68 (1994) 2986-2993
42. Schneider R., Campbell M., Nasioulas G., Felber B.K., and Pavlakis G.N. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol 71 (1997) 4892-4903
43. Biragyn A., Tani K., Grimm M.C., Weeks S., and Kwak L.W. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 17 (1999) 253-258
44. Aberle H., Bauer A., Stappert J., Kispert A., and Kemler R. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16 (1997) 3797-3804
45. Chikhlikar P., Barros De Arruda L., Agrawal S., Byrne B., Guggino W., August J.T., et al. Inverted terminal repeat sequences of adeno-associated virus enhance the antibody and CD8(+) responses to a HIV-1 p55Gag/LAMP DNA vaccine chimera. Virology 323 (2004) 220-232
46. Valentin A., Chikhlikar P., Patel V., Rosati M., Maciel M., Chang K.-H., et al. Comparison of DNA vaccines producing HIV-1 Gag and LAMP/Gag chimera in rhesus macaques reveals antigen-specific T-cell responses with distinct phenotypes. Vaccine 27 (2009) 4840-4849
47. Marques Jr. E.T., Chikhlikar P., De Arruda L.B., Leao I.C., Lu Y., Wong J., et al. HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses. J Biol Chem 278 (2003) 37926-37936
48. De Arruda L.B., Chikhlikar P.R., August J.T., and Marques E.T. DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response. Immunology 112 (2004) 126-133
49. Chikhlikar P., De Arruda L.B., Maciel M., Silvera P., Lewis M.G., August J.T., et al. DNA encoding an HIV-1 Gag/human lysosome-associated membrane protein-1 chimera elicits a broad cellular and humoral immune response in Rhesus macaques. PLoS ONE 1 (2006) e135
50. Jalah R., Rosati R., Kulkarni V., Patel V., Bergamaschi C., Valentin A., et al. Efficient systemic expression of bioactive IL-15 in mice upon delivery of optimized DNA expression plasmids. DNA Cell Biol 26 (2007) 827-840
51. Bergamaschi C., Rosati M., Jalah R., Valentin A., Kulkarni V., Alicea C., et al. Intracellular interaction of interleukin IL-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J Biol Chem 283 (2007) 4189-4199
52. Romano J.W., Shurtliff R.N., Dobratz E., Gibson A., Hickman K., Markham P.D., et al. Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. J Virol Methods 86 (2000) 61-70
53. Mwau M., Cebere I., Sutton J., Chikoti P., Winstone N., Wee E.G., et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 85 (2004) 911-919
54. Graham B.S., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 194 (2006) 1650-1660
55. Catanzaro A.T., Roederer M., Koup R.A., Bailer R.T., Enama M.E., Nason M.C., et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 25 (2007) 4085-4092
56. Eller M.A., Eller L.A., Opollo M.S., Ouma B.J., Oballah P.O., Galley L., et al. Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. Vaccine 25 (2007) 7737-7742
57. Tavel J.A., Martin J.E., Kelly G.G., Enama M.E., Shen J.M., Gomez P.L., et al. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J Acquir Immune Defic Syndr 44 (2007) 601-605
58. Bansal A., Jackson B., West K., Wang S., Lu S., Kennedy J.S., et al. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J Virol 82 (2008) 6458-6469
59. Gorse G.J., Baden L.R., Wecker M., Newman M.J., Ferrari G., Weinhold K.J., et al. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine 26 (2008) 215-223
60. Jaoko W., Nakwagala F.N., Anzala O., Manyonyi G.O., Birungi J., Nanvubya A., et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 26 (2008) 2788-2795
61. Kutzler M.A., and Weiner D.B. DNA vaccines: ready for prime time?. Nat Rev Genet 9 (2008) 776-788
62. Wang S., Kennedy J.S., West K., Montefiori D.C., Coley S., Lawrence J., et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26 (2008) 1098-1110
63. Hartikka J., Bozoukova V., Ferrari M., Sukhu L., Enas J., Sawdey M., et al. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 19 (2001) 1911-1923
64. Fuller D.H., Rajakumar P.A., Wilson L.A., Trichel A.M., Fuller J.T., Shipley T., et al. Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J Virol 76 (2002) 3309-3317
65. Bertley F.M., Kozlowski P.A., Wang S.W., Chappelle J., Patel J., Sonuyi O., et al. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol 172 (2004) 3745-3757
66. Wang S.W., Bertley F.M., Kozlowski P.A., Herrmann L., Manson K., Mazzara G., et al. An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS. AIDS Res Hum Retroviruses 20 (2004) 846-859
67. Dale C.J., Thomson S., De Rose R., Ranasinghe C., Medveczky C.J., Pamungkas J., et al. Prime-boost strategies in DNA vaccines. Methods Mol Med 127 (2006) 171-197
68. Duerr A., Wasserheit J.N., and Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 43 (2006) 500-511
69. Girard M.P., Osmanov S.K., and Kieny M.P. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 24 (2006) 4062-4081
70. Hokey D.A., and Weiner D.B. DNA vaccines for HIV: challenges and opportunities. Springer Semin Immunopathol 28 (2006) 267-279
71. Liu M.A., Wahren B., and Karlsson Hedestam G.B. DNA vaccines: recent developments and future possibilities. Hum Gene Ther 17 (2006) 1051-1061
72. Lori F., Weiner D.B., Calarota S.A., Kelly L.M., and Lisziewicz J. Cytokine-adjuvanted HIV-DNA vaccination strategies. Springer Semin Immunopathol 28 (2006) 231-238
73. Lu S. Combination DNA plus protein HIV vaccines. Springer Semin Immunopathol 28 (2006) 255-265
74. Mcmichael A.J. HIV vaccines. Annu Rev Immunol 24 (2006) 227-255
75. Rodriguez-Chavez I.R., Allen M., Hill E.L., Sheets R.L., Pensiero M., Bradac J.A., et al. Current advances and challenges in HIV-1 vaccines. Curr HIV/AIDS Rep 3 (2006) 39-47
76. Brave A., Ljungberg K., Wahren B., and Liu M.A. Vaccine delivery methods using viral vectors. Mol Pharm 4 (2007) 18-32
77. Hinkula J. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity. Expert Rev Vaccines 6 (2007) 203-212
78. Thorner A.R., and Barouch D.H. HIV-1 vaccine development: progress and prospects. Curr Infect Dis Rep 9 (2007) 71-75
79. Manrique M., Micewicz E., Kozlowski P.A., Wang S.W., Aurora D., Wilson R.L., et al. DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory. AIDS Res Hum Retroviruses 24 (2008) 505-519
80. Tsai C.C., Emau P., Follis K.E., Beck T.W., Benveniste R.E., Bischofberger N., et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 72 (1998) 4265-4273
81. Van Rompay K.K., Dailey P.J., Tarara R.P., Canfield D.R., Aguirre N.L., Cherrington J.M., et al. Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques. J Virol 73 (1999) 2947-2955
82. Emau P., Jiang Y., Agy M.B., Tian B., Bekele G., and Tsai C.C. Post-exposure prophylaxis for SIV revisited: animal model for HIV prevention. AIDS Res Ther 3 (2006) 29
83. Chun T.W., Davey Jr. R.T., Engel D., Lane H.C., and Fauci A.S. Re-emergence of HIV after stopping therapy. Nature 401 (1999) 874-875
84. Davey Jr. R.T., Bhat N., Yoder C., Chun T.W., Metcalf J.A., Dewar R., et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A 96 (1999) 15109-15114
85. Garcia F., Plana M., Vidal C., Cruceta A., O'brien W.A., Pantaleo G., et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. Aids 13 (1999) F79-86
86. Neumann A.U., Tubiana R., Calvez V., Robert C., Li T.S., Agut H., et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. Aids 13 (1999) 677-683
87. Ortiz G.M., Nixon D.F., Trkola A., Binley J., Jin X., Bonhoeffer S., et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 104 (1999) R13-18
88. Ortiz G.M., Wellons M., Brancato J., Vo H.T., Zinn R.L., Clarkson D.E., et al. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A 98 (2001) 13288-13293
89. Oxenius A., Price D.A., Gunthard H.F., Dawson S.J., Fagard C., Perrin L., et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci U S A 99 (2002) 13747-13752